You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. AAAPT Technology for Improving Chemotherapy

    SBC: SCI-ENGI-MEDCO SOLUTIONS, INC            Topic: NCI

    DESCRIPTION provided by applicant Dysregulation of apoptosis pathways and loss of Human Beta Defensin hBD are the common tactics adapted by cancer cells to circumvent the effects of chemotherapy Consequently high dose of chemotherapy is required to obtain a clinically relevant therapeutic index which in turn compromises safety and develops resistance to therapy The problem is acute p ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Adjoint-Based Shape Optimization for Noise Reduction

    SBC: INNOVATIVE TECH APPLICATIONS LLC            Topic: N142099

    ITAC and its partners propose to develop and demonstrate a computational technology and methodology tool for the concurrent automated shaping of aft airframe and nozzle geometries to reduce tactical aircraft jet noise without any performance penalties. The proposed technologies will lead to an integrated tool which inherently maintains critical aerodynamic performance while reducing the noise gene ...

    SBIR Phase I 2014 Department of DefenseNavy
  3. Advancing High Energy Lithium-Sulfur Batteries

    SBC: Yardney Technical Products, Inc.            Topic: Z102

    Lithium-Ion batteries have been a main source of energy for many aerospace applications over the past decade. Future space missions are facing a number of challenging requirements, including significant increase in specific energy, approaching 500 Wh/kg, and energy density of 700 Wh/l at cell level. Compared to state-of-the-art technology today, a reduction in mass and volume are necessary, along ...

    SBIR Phase I 2014 National Aeronautics and Space Administration
  4. A MODEL SYSTEM IS CREATED TO DETERMINE THE FEASIBILITY OF DEVELOPING INTEGRATED COMPUTER SOFTWARE FOR ANATOMIC PATHOLOGY MANAGEMENT INFORMATION.

    SBC: Management Tech Consult Inc.            Topic: N/A

    A MODEL SYSTEM IS CREATED TO DETERMINE THE FEASIBILITY OF DEVELOPING INTEGRATED COMPUTER SOFTWARE FOR ANATOMIC PATHOLOGY MANAGEMENT INFORMATION. THE SOFTWARE COMBINES SEVERAL UNIQUE DIAGNOSTIC CODING FUNCTIONS, IS TRANSPORTABLE TO THE MAJOR COMPUTER ARCHITECTURES, AND IS EFFICIENT THE OBJECTIVES ARE TO: 1. INTEGRATE APPLICABLE PATIENT INFORMATION OBTAINED AUTOMATICALLY FROM HOSPITAL SOURCES DIRECT ...

    SBIR Phase I 1985 Department of Health and Human Services
  5. AN ADVERSE REACTION TO A DRUG WHICH TAKES PLACE WHILE A PATIENT IS ON MEDICATION IS OFTEN IMPOSSIBLE TO DIAGNOSE ACCURATELY.

    SBC: Imbic Corpon            Topic: N/A

    AN ADVERSE REACTION TO A DRUG WHICH TAKES PLACE WHILE A PATIENT IS ON MEDICATION IS OFTEN IMPOSSIBLE TO DIAGNOSE ACCURATELY. THE NATURE OF THE UNDERLYING REACTION MAY HAVE AN IMMUNOLOGIC, TOXICOLOGIC, OR PHARMACOLOGIC BASIS. AMONG THE MOST NOTABLE IMMUNOLOGIC REACTIONS TO DRUGS ARE THOSE WHICH GIVE RISE TO ANTIBODIES THAT, IN THE PRESENCE OF DRUG, ATTACH TO BLOOD CELLS AND DESTROY THEM. THE MOST C ...

    SBIR Phase I 1985 Department of Health and Human Services
  6. A new two-drug combination therapy for noise-induced hearing loss

    SBC: GATEWAY BIOTECHNOLOGY, INC.            Topic: NIDCD

    DESCRIPTION (provided by applicant): Noise is the most common occupational and environmental hazard, thus it is not surprising that noise-induced hearing loss (NIHL) is the second most common form of sensorineural hearing deficit, second only to age-related hearing loss (presbycusis). Although therapeutics that target the free radical pathway have shown promise for reducing NIHL, there are no FDA- ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Anti-virulence FimH inhibitors for the treatment and prevention of UTIs

    SBC: FIMBRION THERAPEUTICS INC            Topic: NIAID

    DESCRIPTION provided by applicant Over million women suffer from urinary tract infections UTI annually in the U S and approximately of these patients suffer from multiple recurrences UTI is unique in its high prevalence of chronic recurrent infections which has caused a tremendous need for long term conventional prophylactic therapy This is leading to increased antimicrobial res ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. A STUDY IS PROPOSED WHICH WILL DETERMINE THE FEASIBILITY OF DEVELOPING A COMPUTER BASED MODEL FOR ADMINISTERING ASSESSMENT AND THERAPY TO MENTALLY RETARDED/DEVELOPMENTALLY DISABLED INFANTS AND CHILDREN.

    SBC: Handicapped Childrens Technolo            Topic: N/A

    A STUDY IS PROPOSED WHICH WILL DETERMINE THE FEASIBILITY OF DEVELOPING A COMPUTER BASED MODEL FOR ADMINISTERING ASSESSMENT AND THERAPY TO MENTALLY RETARDED/DEVELOPMENTALLY DISABLED INFANTS AND CHILDREN. THE PRINCIPAL AIM OF PHASE I IS TO SURVEY CURRENT TECHNOLOGIES AS THEY RELATE TO THERAPY AND PROVIDE A BASIS FOR A PHASE II RESEARCH PLAN. HARDWARE AND SOFTWARE BASED SIMULATION OF A MODEL WILL BE ...

    SBIR Phase I 1985 Department of Health and Human Services
  9. BETA-ENDORPHIN (BE) IS A PEPTIDE COMPOSED OF THE 30 CARBOXYL-TERMINAL RESIDUES OF BETA-LIPOTROPIN (BLPH).

    SBC: Imbic Corpon            Topic: N/A

    BETA-ENDORPHIN (BE) IS A PEPTIDE COMPOSED OF THE 30 CARBOXYL-TERMINAL RESIDUES OF BETA-LIPOTROPIN (BLPH). IT HAS BEEN SHOWN TO BE A NATURALLY OCCURRING OPIATE, AS WELL AS TO POSSESS NONOPIATE RELATED BIOACTIVITY. CURRENT ASSAY TECHNIQUES ARE INADEQUATE DUE TO LACK OF IMMUNOLOGICAL SPECIFICITY RESULTING FROM CROSS-REACTING OF BE AND BLPH WITH THE SAME ANTIBODIES. A SEPARATION METHOD UTILIZING THE S ...

    SBIR Phase I 1985 Department of Health and Human Services
  10. Calcaftor, a CFTR stabilizer for Cystic Fibrosis treatment

    SBC: CALISTA THERAPEUTICS INC            Topic: NIDDK

    DESCRIPTION (provided by applicant): Calista Therapeutics has invented Calcaftor, a first-in-class peptide drug that can treat all Cystic Fibrosis (CF) patients. Calcaftor is validated in the gold standard pre-clinical model of CF using F508 -CFTR lung tissue harvested from CF transplant patients. Results from this model demonstrated a gt25 hour duration of action that enables once daily inhaled n ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government